(via Thenewswire.ca)
Singapore, April 2, 2012 - Zecotek Photonics Inc. (TSX-V: ZMS;
Frankfurt: W1I), a developer of leading-edge photonics technologies
for medical, industrial and scientific markets, today announced that
the ALICE Experiment at the European Organization for Nuclear Research
(CERN), Switzerland, has ordered its patented third generation
Micro-pixel Avalanche Photo Diodes (MAPD-3N). The order follows the
results of a test bench study on the characteristics of the MAPD
conducted by the University of Bergen in Norway, and the previously
announced MAPD orders from the four other CERN experiments: the Swiss
Federal Institute of Technology, the Joint Institute for Nuclear
Research, the Compact Muon Solenoid experiment and multiple MAPD
orders from the NA61 Experiment.
"We have vigorously tested Zecotek's solid-state MAPD-3N photo
detectors and the device proved to offers a number of attractive
properties for use in calorimeters with respect to: low bias voltage,
quantum efficiency, radiation hardness and timing resolution,"
said
Dr. Petr Nomokonov, representative of the ALICE Experiment. "We
have been searching for a replacement for the APD which is an older
photon counting technology. Zecotek's MAPD is a great solution due to
its compactness, radiation hardness and other scientific and technical
advantages."
"The ALICE Experiment is the fifth project at CERN using our
solid-state MAPD photo detectors and our relationship with the various
scientific teams at CERN continues to deepen," said Dr. A.F.
Zerrouk, Chairman, President, and CEO of Zecotek. "Our third
generation solid-state MAPD photo detectors have become the favoured
detection device replacing older photon detection technologies. CERN
is one of the world's most important centres for scientific research
and requires large volumes of compact photo detectors which are
insensitive to radiation and magnetic fields. Our MAPD continues to
outperform competing technologies and we expect additional orders in
the future."
ALICE is the acronym for "A Large Ion Collide Experiment",
one of the largest experiments in the world devoted to research in the
physics of matter at an infinitely small scale. Hosted at CERN, this
project involves an international collaboration of more than 1000
physicists, engineers and technicians, including around 200 graduate
students, from 105 physics institutes in 30 countries across the
world. The ALICE Experiment is in search of answers to fundamental
scientific questions, using the extraordinary tools provided by the
Large Hadron Collider. For more information please visit:
http://aliceinfo.cern.ch/Public/Welcome.html.
About CERN
CERN, the European Organization for Nuclear Research, is one of the
world's largest and most respected centres for scientific research.
Its business is fundamental physics, finding out what the Universe is
made of and how it works. At CERN, the world's largest and most
complex scientific instruments are used to study the basic
constituents of matter -- the fundamental particles. By studying what
happens when these particles collide, physicists learn about the laws
of Nature. CERN is the home of the Large Hadron Collider (LHC). LHC
experiments will address questions such as what gives matter its mass,
what the invisible 96% of the Universe is made of, why nature prefers
matter to antimatter and how matter evolved from the first instants of
the Universe's existence. The instruments used at CERN are particle
accelerators and detectors. Accelerators boost beams of particles to
high energies before they are made to collide with each other or with
stationary targets. Detectors observe and record the results of these
collisions. Founded in 1954, the CERN Laboratory sits astride the
Franco-Swiss border near Geneva. It was one of Europe's first joint
ventures and now has 20 Member States. For more information about CMS
please visit http://cms.web.cern.ch/cms/Detector/WhatCMS/index.html.
About Zecotek
Zecotek Photonics Inc (TSX-V: ZMS; Frankfurt: W1I) is a photonics
technology company developing high-performance crystals, photo
detectors, medical lasers, optical imaging and 3D display technologies
for commercial applications in the medical diagnostics and high-tech
industry. Founded in 2003, the company has three distinct operating
divisions: medical imaging, medical lasers and 3D display and labs
located in Canada, Singapore and Russia. Zecotek commercializes its
novel, patented and patent-pending bio-photonic technologies directly
and through strategic alliances and joint ventures with multinational
OEMs, distributors and other industry leaders. For more information,
please visit www.zecotek.com.
This press release may contain forward-looking statements that are
based on management's expectations, estimates, projections and
assumptions. These statements are not guarantees of future performance
and involve certain risks and uncertainties, which are difficult to
predict. Therefore, actual future results and trends may differ
materially from what may have been stated.
For Additional Information Please Contact:
-------------------------------------------------------------
|Zecotek Photonics Inc.       |CHF Investor Relations |
|Michael Minder |Julia Clark, Account Manager|
|T: (604) 783-8291Â Â Â |T: (416) 868-1079 x236 |
|ir@zecotek.com |julia@chfir.com |
-------------------------------------------------------------
Copyright (c) 2012 Thenewswire.ca - All rights reserved.
© 2024 Canjex Publishing Ltd. All rights reserved.